{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T13:57:57Z","timestamp":1792936677802,"version":"4.5.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Psoriasis and hidradenitis suppurativa are chronic inflammatory skin diseases that can develop together, negatively impacting on the patient\u2019s quality of life. We aimed to review the most up-to-date information regarding the epidemiology, pathogenesis, clinical presentation and possible therapeutical choices in patients with both psoriasis and hidradenitis suppurativa, thus linking these two autoimmune and autoinflammatory conditions. A narrative review of articles dating from 2017 to 2022 has been performed using the PubMed database. We analyzed the case reports and case series found in the literature regarding patients who suffered from both psoriasis and HS. Psoriasis arose before hidradenitis suppurativa in the majority of cases, while only a minority of them had hidradenitis suppurativa before psoriasis. Interestingly, some patients suffered from paradoxical hidradenitis suppurativa following biological therapy administered to treat the already present psoriasis. Lastly, new biological drugs have been marketed with great success for the outcome of psoriasis, but similar progress did not happen for hidradenitis. Novel therapeutic approaches and lines of research are needed for the treatment of these pathologies, even if concomitant, in order to improve patient\u2019s quality of life.<\/jats:p>","DOI":"10.3389\/fmed.2023.1208817","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T06:17:47Z","timestamp":1688710667000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Hidradenitis suppurativa and psoriasis: the odd couple"],"prefix":"10.3389","volume":"10","author":[{"given":"Laura","family":"Macca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Li Pomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ylenia","family":"Ingrasciotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3390\/biomedicines9111594","article-title":"Neoplastic implications in patients suffering from hidradenitis Suppurativa under systemic treatments","volume":"9","author":"Li Pomi","year":"2021","journal-title":"Biomedicine"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Hidradenitis Suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.3390\/biomedicines10112761","article-title":"Hidradenitis Suppurativa in patients with HIV: a scoping review","volume":"10","author":"Macca","year":"2022","journal-title":"Biomedicine"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.4103\/jfmpc.jfmpc_795_21","article-title":"Hidradenitis suppurativa; classification, remedies, etiology, and comorbidities; a narrative review","volume":"10","author":"Mohammadi","year":"2021","journal-title":"J Family Med Prim Care"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s13555-022-00758-2","article-title":"Update on the Management of Pediatric Psoriasis: an Italian consensus","volume":"12","author":"Peris","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref7","volume-title":"World Health Organization Global Report on Psoriasis","year":"2022"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Investig Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/biomedicines10020228","article-title":"Novel therapeutic approaches to psoriasis and risk of infectious disease","volume":"10","author":"Motolese","year":"2022","journal-title":"Biomedicine"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2340\/00015555-2937","article-title":"Auditory system involvement in psoriasis","volume":"98","author":"Borgia","year":"2018","journal-title":"Acta Dermatol Venereol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.23736\/S0392-0488.18.06054-6","article-title":"Anti-TNF\u03b1-induced psoriasis under treatment of hidradenitis suppurativa: report of 2 cases","volume":"155","author":"Musumeci","year":"2020","journal-title":"G Ital Dermatol Venereol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"788","DOI":"10.23736\/S0392-0488.18.06135-7","article-title":"Ixekizumab in hidradenitis suppurativa in a psoriatic patient","volume":"155","author":"Odorici","year":"2021","journal-title":"G Ital Dermatol Venereol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e12742","DOI":"10.1111\/dth.12742","article-title":"Development of hidradenitis suppurativa in a patient treated with ustekinumab for her psoriasis: a potential paradoxical reaction?","volume":"31","author":"Gkini","year":"2018","journal-title":"Dermatol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e18991","DOI":"10.1097\/MD.0000000000018991","article-title":"Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients","volume":"99","author":"Garcovich","year":"2020","journal-title":"Medicine"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1111\/ijd.15704","article-title":"A case of moderate hidradenitis suppurativa and psoriasis successfully treated with risankizumab","volume":"61","author":"Licata","year":"2022","journal-title":"Int J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/1346-8138.15807","article-title":"Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: a possible involvement of Th17 across the spectrum of both diseases","volume":"48","author":"Yoshida","year":"2021","journal-title":"J Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jdcr.2020.08.032","article-title":"T-cell\/histiocyte-rich large B-cell lymphoma in a 27-year-old with hidradenitis suppurativa, psoriasis, and vitiligo: implications for screening","volume":"6","author":"Vellaichamy","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dth.13150","article-title":"Secukinumab-induced paradoxical hidradenitis suppurativa","volume":"33","author":"Navarro-Trivi\u00f1o","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e13089","DOI":"10.1111\/dth.13089","article-title":"One drug and two diseases: a case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast","volume":"32","author":"Lanna","year":"2019","journal-title":"Dermatol Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e13448","DOI":"10.1111\/dth.13448","article-title":"A case of hidradenitis suppurativa successfully treated with apremilast in a patient with psoriasis andSAMPUS","volume":"33","author":"Proietti","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.12688\/f1000research.21216.2","article-title":"Case report: treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches","volume":"8","author":"Tampouratzi","year":"2020","journal-title":"F1000Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.abd.2019.02.012","article-title":"PsAPASH: a rare and recent autoinflammatory syndrome associated with hidradenitis suppurativa","volume":"95","author":"De Lima Gadelha","year":"2020","journal-title":"An Bras Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"462","DOI":"10.5021\/ad.2018.30.4.462","article-title":"A case of moderate hidradenitis Suppurativa and psoriasis treated with Secukinumab","volume":"30","author":"Giuseppe","year":"2018","journal-title":"Ann Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4103\/ijdvl.IJDVL_455_18","article-title":"Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: a case series","volume":"87","author":"Yen","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1016\/j.jaad.2018.11.036","article-title":"Psoriasis and hidradenitis Suppurativa: a large-scale population-based study","volume":"88","author":"Kridin","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1111\/jdv.15071","article-title":"Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study","volume":"32","author":"Lee","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3899\/jrheum.130977","article-title":"Hidradenitis Suppurativa associated with Spondyloarthritis\u2013results from a multicenter National Prospective Study","volume":"41","author":"Richette","year":"2014","journal-title":"J Rheumatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jaad.2015.06.050","article-title":"Epidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): experience of a tertiary medical center","volume":"73","author":"Patel","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CCID.S111019","article-title":"Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment","volume":"10","author":"Napolitano","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"204062232110559","DOI":"10.1177\/20406223211055920","article-title":"New perspectives on the treatment of hidradenitis suppurativa","volume":"12","author":"Amat-Samaranch","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.3390\/biomedicines10082039","article-title":"Hidradenitis Suppurativa: a perspective on genetic factors involved in the disease","volume":"10","author":"Moltrasio","year":"2022","journal-title":"Biomedicine"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa","volume":"82","author":"Goldburg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"9716","DOI":"10.3390\/ijms23179716","article-title":"Immunomodulatory drugs in the treatment of hidradenitis Suppurativa\u2014possibilities and limitations","volume":"23","author":"\u015awierczewska","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.26444\/aaem\/112107","article-title":"Environmental risk factors and epigenetic alternations in psoriasis","volume":"27","author":"Roszkiewicz","year":"2020","journal-title":"Ann Agric Environ Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.3390\/ijms23094874","article-title":"Epigenetic mechanisms of epidermal differentiation","volume":"23","author":"Moltrasio","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11154-016-9328-5","article-title":"Evidence-based approach to the treatment of hidradenitis suppurativa\/acne inversa, based on the European guidelines for hidradenitis suppurativa","volume":"17","author":"Gulliver","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.clindermatol.2020.10.016","article-title":"PASH, PAPASH, PsAPASH, and PASS: the autoinflammatory syndromes of hidradenitis suppurativa","volume":"39","author":"Garcovich","year":"2021","journal-title":"Clin Dermatol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000511045","article-title":"Hidradenitis Suppurativa: proposal of classification in two Endotypes with two-step cluster analysis","volume":"237","author":"Gonz\u00e1lez-Manso","year":"2021","journal-title":"Dermatology"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/srt.12823","article-title":"Advanced evaluation of hidradenitis suppurativa with ultra-high frequency ultrasound: a promising tool for the diagnosis and monitoring of disease progression","volume":"26","author":"Oranges","year":"2020","journal-title":"Skin Res Technol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"235","DOI":"10.23736\/S2784-8671.18.06196-5","article-title":"Comparison of clinical and sonographic scores in hidradenitis suppurativa and proposal of a novel ultrasound scoring system. Italian journal of","volume":"156","author":"Nazzaro","year":"2021","journal-title":"Dermatol Venereol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/bjd.17537","article-title":"British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018","volume":"180","author":"Ingram","year":"2019","journal-title":"Br J Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2340\/00015555-2513","article-title":"Hurley staging refined: a proposal by the Dutch hidradenitis Suppurativa expert group","volume":"97","author":"Horv\u00e1th","year":"2017","journal-title":"Acta Dermatol Venereol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the international hidradenitis Suppurativa severity score system (IHS4), a novel dynamic scoring system to assess HS","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"ref47","first-page":"192","article-title":"The many variants of psoriasis","volume":"69","author":"Clebak","year":"2020","journal-title":"J Fam Pract"},{"key":"ref48","first-page":"1","volume-title":"Evidence-based psoriasis: overview and diagnosis","author":"Kimmel","year":"2018"},{"key":"ref49","first-page":"S403","article-title":"Contemporary management of moderate to severe plaque psoriasis","volume":"23","author":"Wu","year":"2017","journal-title":"Am J Manag Care"},{"key":"ref50","first-page":"278","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim","year":"2017","journal-title":"Can Fam Physician"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: a European consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch Dermatol Res"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fphar.2019.00282","article-title":"Paradoxical skin reactions to biologics in patients with rheumatologic disorders","volume":"10","author":"Garcovich","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/09546634.2015.1094179","article-title":"Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa","volume":"27","author":"Delobeau","year":"2016","journal-title":"J Dermatol Treat"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jaad.2016.01.018","article-title":"Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases","volume":"74","author":"Faivre","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jdcr.2018.12.002","article-title":"Secukinumab and hidradenitis suppurativa: friends or foes?","volume":"5","author":"Marasca","year":"2019","journal-title":"JAAD Case Rep"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"13","DOI":"10.23736\/S2784-8671.19.06209-6","article-title":"Hidradenitis suppurativa associated with systemic lupus erythematosus and psoriasis: a therapeutical challenge","volume":"156","author":"Nazzaro","year":"2022","journal-title":"Ital J Dermatol Venereol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00403-020-02152-4","article-title":"Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions","volume":"313","author":"Chu","year":"2021","journal-title":"Arch Dermatol Res"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis Suppurativa foundations","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2217\/imt-2018-0090","article-title":"Biologics for hidradenitis suppurativa: an update","volume":"11","author":"W\u0142odarek","year":"2019","journal-title":"Immunotherapy"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.3390\/ijms23073753","article-title":"New and emerging targeted therapies for hidradenitis Suppurativa","volume":"23","author":"Markota \u010cagalj","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1684\/ejd.2012.1795","article-title":"Efficacy and tolerance of prolonged infliximab treatment of moderate-to-severe forms of hidradenitis suppurativa","volume":"22","author":"Lesage","year":"2012","journal-title":"Eur J Dermatol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jaad.2019.09.071","article-title":"High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa","volume":"82","author":"Ghias","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref63","first-page":"36","article-title":"Non-response to Interleukin-1 antagonist Canakinumab in two patients with refractory pyoderma Gangrenosum and hidradenitis Suppurativa","volume":"10","author":"Sun","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamadermatol.2017.2392","article-title":"Canakinumab for severe hidradenitis Suppurativa","volume":"153","author":"Houriet","year":"2017","journal-title":"JAMA Dermatol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1684\/ejd.2013.2018","article-title":"Pyoderma gangrenosum and concomitant hidradenitis suppurativa \u2013 rapid response to canakinumab (anti-IL-1\u03b2)","volume":"23","author":"Jaeger","year":"2013","journal-title":"Eur J Dermatol"},{"key":"ref66","volume-title":"Molecular characteristics of Brodalumab in hidradenitis Suppurativa","author":"Renert-Yuval","year":"2022"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"e15866","DOI":"10.1111\/dth.15866","article-title":"Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: real-life experience and therapeutic response to other biological drugs","volume":"35","author":"Burzi","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1159\/000524174","article-title":"Clinical and epidemiological characteristics of hidradenitis Suppurativa patients with paradoxical Psoriasiform reactions following treatment with adalimumab","volume":"8","author":"Kanelleas","year":"2022","journal-title":"Skin Appendage Disord"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1208817\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T06:17:56Z","timestamp":1688710676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1208817\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":68,"alternative-id":["10.3389\/fmed.2023.1208817"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1208817","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"article-number":"1208817"}}